Login to Your Account



Celldex Adds $40M Publicly for Immunotherapy Pipeline

By Jennifer Boggs
Managing Editor

Monday, February 27, 2012

Nearly three months into its pivotal study of lead immunotherapy candidate rindopepimut in a subset of glioblastoma multiforme (GBM) patients, Celldex Therapeutics Inc. is pulling in about $40.4 million in a public offering to help support that study and advance earlier pipeline programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription